Angeion v. Cardiac Pacemakers, Inc.
This article was originally published in The Gray Sheet
Magistrate judge recommends in a Report and Recommendation that a Minneapolis district court judge grant Angeion's motions for summary judgment and deny the Guidant subsidiary's counter motions for summary judgment of non-infringement that its Mini I and II automatic implantable cardioverter defibrillators infringe certain claims of three Angeion patents related to smaller size, smaller capacitance and "Hot Can-like" features of Angeion devices. The judge also recommends that a claim related to a fourth Angeion patent be dismissed. Angeion and CPI have up to twenty days to file responses to the report, after which time the district court judge will make a final ruling. A jury will consider sometime this fall claims of validity and enforceability of the patents, as well as any possible damages or willful infringement...
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.